Pharmacokinetics of dacarbazine (DTIC) in pregnancy.
Cancer chemotherapy and pharmacology
Dacarbazine; Metabolites; Pharmacokinetics; Pregnancy
PURPOSE: The purpose of this report is to describe, for the first time, the pharmacokinetics of dacarbazine (DTIC) and its metabolites [5-[3-methyl-triazen-1-yl]-imidazole-4-carboxamide (MTIC), 5-[3-hydroxymethyl-3-methyl-triazen-1-yl]-imidazole-4-carboxamide (HMMTIC) and 5-aminoimidazole-4-carboxamide (AIC)] during pregnancy (n = 2) and postpartum (n = 1).
METHODS: Non-compartmental DTIC, MTIC, HMMTIC, and AIC pharmacokinetics (PK) were estimated in one case at 29 week gestation and 18 day postpartum and a second case at 32 week gestation, in women receiving DTIC in combination with doxorubicin, bleomycin, and vinblastine for treatment of Hodgkin's lymphoma. Drug concentrations were measured by HPLC.
RESULTS: In the subject who completed both pregnancy and postpartum study days, DTIC area under the concentration-time curve (AUC) was 27% higher and metabolite AUCs were lower by 27% for HMMTIC, 38% for MTIC, and 83% of AIC during pregnancy compared to postpartum. At 7 and 9 year follow-up, both subjects were in remission of their Hodgkin's lymphoma.
CONCLUSIONS: Based on these two case reports, pregnancy appears to decrease the metabolism of the pro-drug dacarbazine, likely through inhibition of CYP1A2 activity. Lower concentrations of active metabolites and decreased efficacy may result, although both these subjects experienced long-term remission of their Hodgkin's lymphoma.
Women & Children
Obstetrics & Gynecology
Kantrowitz-Gordon, Ira; Hays, Karen; Kayode, Olumide; Kumar, Aditya R; Kaplan, Henry G; Reid, Joel M; Safgren, Stephanie L; Ames, Matthew M; Easterling, Thomas R; and Hebert, Mary F, "Pharmacokinetics of dacarbazine (DTIC) in pregnancy." (2018). Journal Articles and Abstracts. 45.